Order Article Reprints

López-Abad A, Belmonte M, Ramírez Backhaus M, Server Gómez G, Cao Avellaneda E, Moreno Alarcón C, López Cubillana P, Yago Giménez P, de Pablos Rodríguez P, Juan Fita MJ, et al. Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study. Journal of Clinical Medicine. 2024; 13(20):6221. https://doi.org/10.3390/jcm13206221

López-Abad, Alicia, Mario Belmonte, Miguel Ramírez Backhaus, Gerardo Server Gómez, Enrique Cao Avellaneda, Cristóbal Moreno Alarcón, Pedro López Cubillana, Pablo Yago Giménez, Pedro de Pablos Rodríguez, María José Juan Fita, and et al. 2024. "Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study" Journal of Clinical Medicine 13, no. 20: 6221. https://doi.org/10.3390/jcm13206221

López-Abad, A., Belmonte, M., Ramírez Backhaus, M., Server Gómez, G., Cao Avellaneda, E., Moreno Alarcón, C., López Cubillana, P., Yago Giménez, P., de Pablos Rodríguez, P., Juan Fita, M. J., Climent Durán, M. Á., Guardiola Ruiz, I., Vidal Crespo, N., Moreno Avilés, J., Guzmán Martínez-Valls, P. L., & López González, P. Á. (2024). Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study. Journal of Clinical Medicine, 13(20), 6221. https://doi.org/10.3390/jcm13206221